Skip to content
May 08 2015

Small Cap Biotech Valuations: Proceed With Caution

  • May 8, 2015

While Large/Mid Cap Biotechnology companies are boasting rising profitability, better cash flows, and stronger drug pipelines, the Small/Micro Cap Biotech firms, in general, have little tangible to show and valuations may be above the comfort zone.


For full access, please enter your credentials.

About The Author

Jun Zhu / Sr. Research Analyst & Co-Portfolio Manager